FATE Overview

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.

Wall Street analysts forecast FATE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FATE is4.64 USD with a low forecast of 2.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Fate Therapeutics Inc revenue for the last quarter amounts to 1.30M USD, decreased -20.26

Fate Therapeutics Inc. EPS for the last quarter amounts to -0.26 USD, decreased -18.75

Fate Therapeutics Inc (FATE) has 161 emplpoyees as of June 21 2026.

Today FATE has the market capitalization of 243.61M USD.